Adaptimmune Therapeutics PLC (ADAP)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 13,677 | 7,285 | 40,901 | 128,231 |
| General and administrative expense | - | - | - | 19,083 |
| Selling, general and administrative | 18,485 | 23,282 | 21,277 | - |
| Research and development | 22,979 | 28,857 | 34,304 | 40,448 |
| Cost of goods sold | 2,501 | 879 | - | - |
| Total operating expenses | 43,965 | 53,018 | 55,581 | 59,531 |
| (loss)/profit from operations | -30,288 | -45,733 | -14,680 | 68,700 |
| Interest income | 233 | 910 | - | - |
| Interest expense | 962 | 1,881 | 1,109 | 526 |
| Other income (expense), net | 1,289 | -305 | -3,093 | 497 |
| Interest income, debt securities, available-for-sale, operating | - | - | 2,096 | 1,376 |
| (loss)/profit before income tax expense | -29,728 | -47,009 | -16,786 | 70,047 |
| Income tax expense | 612 | 575 | 831 | 526 |
| Net (loss)/profit attributable to ordinary shareholders | -30,340 | -47,584 | -17,617 | 69,521 |
| Earnings per share, basic | -0.02 | -0.03 | -0.01 | 0.05 |
| Earnings per share, diluted | -0.02 | -0.03 | -0.01 | 0.04 |
| Weighted average shares outstanding, basic | 1,584,522,868 | 1,542,159,622 | 1,534,613,977 | 1,533,531,837 |
| Weighted average shares outstanding, diluted | 1,584,522,868 | 1,542,159,622 | 1,534,613,977 | 1,559,183,774 |